NFM — Neurofilament Medium Chain

Migration, Crosslink

📖

NFM — Neurofilament Medium Chain

active

wiki page Created: 2026-04-02T07:19:20 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-nfm

📖 Wiki Page

gene2470 wordssynced 2026-04-02

NFM — Neurofilament Medium Chain

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NFM — Neurofilament Medium Chain</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NFM</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurofilament Medium Chain</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>8p21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4741" target="_blank">4741</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104722" target="_blank">ENSG00000104722</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P12036" target="_blank">P12036</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Intermediate filament protein</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Central and peripheral neurons</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

NFM — Neurofilament Medium Chain

Pathway / Interaction Diagram

...

NFM — Neurofilament Medium Chain

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NFM — Neurofilament Medium Chain</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NFM</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurofilament Medium Chain</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>8p21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4741" target="_blank">4741</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104722" target="_blank">ENSG00000104722</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P12036" target="_blank">P12036</a></td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Intermediate filament protein</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Central and peripheral neurons</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

NFM — Neurofilament Medium Chain

Pathway / Interaction Diagram

Mermaid diagram (expand to render)

Introduction

The NFM (Neurofilament Medium Chain) gene encodes the medium subunit of neuronal intermediate filaments, a critical component of the neuronal cytoskeleton. Located on chromosome 8p21.2, NFM is expressed predominantly in [neurons](/entities/neurons) of the central and peripheral nervous systems, where it plays an essential role in maintaining axonal structure, caliber, and function. Neurofilaments, together with [NEFL](/genes/nefl) (neurofilament light chain) and [NEFH](/genes/nefh) (neurofilament heavy chain), form the intermediate filament network that provides structural support to axons and regulates axonal transport. [@marquez-lopera2024]

In recent years, neurofilament proteins have emerged as highly valuable biomarkers for neurodegenerative diseases. When axons are damaged, neurofilament proteins are released into the cerebrospinal fluid (CSF) and blood, where they can be measured to assess the degree of axonal injury. This has made NFM and its companion proteins critical tools in both clinical research and diagnostic settings. [@khalil2020]

Gene Structure and Expression

The NFM gene spans approximately 8.5 kb on chromosome 8p21.2 and consists of 10 exons encoding a protein of 916 amino acids. The gene is expressed exclusively in neurons, with highest levels in large-diameter myelinated axons of the peripheral and central nervous systems. [@leyer2012]

Tissue Distribution

NFM is expressed in:

Motor [neurons](/cell-types/motor-neurons) of the spinal cord
Sensory [neurons](/cell-types/sensory-neurons) in dorsal root ganglia
[Cortical neurons](/cell-types/cortical-neurons) in the [cerebral cortex](/brain-regions/cortex)
[Hippocampal neurons](/brain-regions/hippocampus)
Pyramidal cells in the [brain](/brain-regions/)
Peripheral nerve fibers
Autonomic nervous system neurons

Transcriptional Regulation

NFM expression is regulated by transcription factors including:

NF-κB signaling pathways
cAMP response element-binding protein (CREB)
Neuronal activity-dependent mechanisms

The gene promoter contains elements responsive to neuronal differentiation signals, ensuring neuron-specific expression throughout development and adulthood. [@petzold2007]

Protein Structure and Function

Structural Organization

Neurofilament medium chain (NF-M) is a member of the intermediate filament protein family. The protein consists of:

N-terminal head domain (approximately 100 amino acids): Contains regulatory sequences and phosphorylation sites

Central α-helical rod domain (approximately 310 amino acids): Forms the coiled-coil structure enabling filament assembly

C-terminal tail domain (approximately 400 amino acids): Contains multiple phosphorylation sites that regulate axonal caliber

The rod domain drives dimer formation through coiled-coil interactions, with dimers assembling into tetramers and then into the mature 10 nm intermediate filament structure. [@bergman2022]

Phosphorylation

The tail domain of NFM contains over 50 potential phosphorylation sites, primarily on serine and threonine residues. Phosphorylation is dynamic and regulated by:

Protein kinase A (PKA): Phosphorylates tail domain sites
Protein kinase C (PKC): Regulates head domain phosphorylation
CDK5: Key kinase in neuronal phosphorylation
MAP kinases: Respond to cellular stress

Phosphorylation state determines the spacing between neurofilament side chains, directly affecting axonal caliber. Heavily phosphorylated NF-M extends further from the filament backbone, increasing axonal diameter. [@leyer2012]

Assembly and Dynamics

Neurofilament assembly is a tightly regulated process:

Dimer formation: NFM and NEFL form heterodimers via their rod domains

Tetramer formation: Two dimers associate antiparallelally

Filament elongation: Tetramers assemble end-to-end and side-by-side

Cross-linking: NEFH cross-bridges stabilize the network

Proper neurofilament assembly requires:

Correct stoichiometry of NFM:NEFL:NEFH
Appropriate phosphorylation state
Presence of assembly cofactors

Role in Axonal Biology

Axonal caliber regulation

NFM plays a critical role in determining axonal diameter through its phosphorylation state. In myelinated axons, larger diameter axons have more heavily phosphorylated NF-M tails, creating greater inter-filament repulsion and thus larger axonal caliber. This relationship is essential for efficient nerve conduction velocity. [@leyer2012]

Axonal transport

Neurofilaments are transported along axons via slow axonal transport mechanisms:

Anterograde transport: Move from cell body toward synapse
Retrograde transport: Return from synapse to cell body
Stationary population: A significant fraction remains stationary

Transport is mediated by motor proteins including kinesins and dyneins, with neurofilament phosphorylation influencing motor protein binding and transport efficiency. [@pantsiou2020]

Myelination effects

Proper NFM function is required for efficient [myelination](/mechanisms/myelination):

NFM-deficient mice show reduced axonal caliber
Myelin thickness is reduced in NFM knockout animals
Node of Ranvier organization is altered
Saltatory conduction is impaired

Disease Associations

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers), neurofilament proteins are elevated in CSF and blood, reflecting axonal degeneration:

CSF NFM levels correlate with disease severity
NFM is elevated in prodromal AD stages
Higher levels predict more rapid cognitive decline
NFM complements tau and β-amyloid biomarkers

The combination of NFM with [tau](/proteins/tau), [β-amyloid](/proteins/amyloid-beta), and neurofilament light chain (NfL) provides comprehensive assessment of neurodegeneration. [@oeckl2022]

Parkinson's Disease

Neurofilament markers are elevated in [Parkinson's disease](/diseases/parkinsons-disease) and correlate with:

Disease progression rate
Cognitive impairment severity
Motor complication development
Risk of developing dementia

CSF and blood NFM levels are higher in PD patients compared to controls, with the highest levels seen in patients with atypical parkinsonian syndromes. [@pantsiou2020] [@petersen2022]

Amyotrophic Lateral Sclerosis (ALS)

[ALS](/diseases/amyotrophic-lateral-sclerosis) shows some of the most dramatic neurofilament elevations:

NFM in CSF is a well-established biomarker
Levels correlate with disease progression rate
Used for patient stratification in clinical trials
Rising levels predict more rapid decline

Neurofilament measurement has become a standard endpoint in ALS clinical trials, with both NFM and NfL used to assess treatment effects. [@lin2021] [@iris2020]

Charcot-Marie-Tooth Disease

[Charcot-Marie-Tooth disease](/diseases/charcot-marie-tooth-disease) (CMT) is directly associated with NFM mutations:

NFM mutations cause CMT2E (autosomal dominant)
Typical phenotype: intermediate CMT
Variable age of onset
Often associated with vocal cord paralysis

Over 20 pathogenic NFM mutations have been described, affecting filament assembly, phosphorylation, and stability.

Multiple Sclerosis

In [multiple sclerosis](/diseases/multiple-sclerosis), NFM reflects axonal injury:

Elevated CSF NFM during relapses
Progressive NFM elevation in secondary progressive MS
Predicts long-term disability accumulation
Used to monitor treatment response

Blood NFM and NfL are now routinely used in MS clinical care to detect disease activity and treatment response. [@kuhle2019]

Huntington's Disease

[Neurofilament levels in Huntington's disease](/diseases/huntington's-disease) correlate with disease progression:

Elevated in premanifest and manifest HD
Correlates with CAG repeat length
Predicts conversion from premanifest to manifest
Reflects white matter pathology

NFM may serve as a marker for evaluating disease-modifying therapies. [@nakamura2021]

Creutzfeldt-Jakob Disease

In prion diseases including [Creutzfeldt-Jakob disease](/diseases/creutzfeldt-jakob-disease):

Very high NFM levels in CSF
Used as a supportive diagnostic marker
Helps differentiate from other dementias
Levels correlate with disease progression

The combination of 14-3-3 protein and NFM in CSF improves diagnostic accuracy. [@chohan2020]

Other Neurodegenerative Conditions

NFM elevation is seen in numerous other conditions:

Frontotemporal dementia: Elevated NFM in CSF
Vascular dementia: NFM reflects vascular injury
Traumatic brain injury: NFM as biomarker for axonal injury
Spinal cord injury: NFM indicates axonal damage
Guillain-Barré syndrome: Elevated in acute phases

Biomarker Applications

Cerebrospinal Fluid Testing

CSF NFM measurement is performed using:

ELISA (enzyme-linked immunosorbent assay)
Single molecule array (Simoa) for enhanced sensitivity
Western blot for molecular weight analysis

Normal CSF NFM reference ranges:

Adults: < 50 ng/mL (varies by assay)
Elevation above 100 ng/mL suggests significant axonal injury

Blood Testing

Blood (serum/plasma) NFM measurement has advantages:

Less invasive than lumbar puncture
Suitable for repeated sampling
Can be used in clinical trials

The Simoa platform enables detection of low concentrations in blood, making NFM a practical blood biomarker. [@bridel2019] [@gaetani2019]

Clinical Utility

NFM biomarker applications include:

Differential diagnosis: Helps distinguish between neurodegenerative conditions

Prognosis: Predicts disease progression rate

Monitoring: Tracks treatment response

Clinical trials: Endpoint for efficacy assessment

Early detection: Identifies axonal damage before symptoms

Therapeutic Implications

Drug Development

Neurofilament biomarkers are used in drug development:

Patient stratification based on baseline NFM levels
Enrichment strategies for clinical trials
Surrogate endpoints for accelerated approval
Dose-response monitoring

Therapeutic Targets

Understanding NFM biology suggests potential interventions:

Neuroprotective strategies to prevent axonal injury
Kinase inhibitors to modulate phosphorylation
Gene therapy approaches for CMT
Small molecules to stabilize neurofilament network

Interaction Network

Protein Interactions

NFM interacts with:

NEFL: Essential for filament assembly
NEFH: Provides cross-linking
Plectin: Links to other cytoskeletal elements
Dynamitin: Modulates transport
Kinesin/dynein: Motor protein binding

Signaling Pathways

NFM is regulated by multiple signaling pathways:

cAMP/PKA signaling
PKC signaling
MAPK/ERK pathway
CDK5 signaling
Calcium-dependent pathways

Research Directions

Current research directions include:

Standardization: Harmonizing NFM measurement across labs

Reference materials: Developing certified reference standards

Longitudinal studies: Understanding NFM trajectories

Multi-marker panels: Combining NFM with other biomarkers

Blood vs CSF comparison: Establishing blood-based testing

Genetic studies: Identifying NFM variants affecting risk

Mouse Models and Research Insights

NFM Knockout Mice

NFM-deficient mice have provided critical insights into neurofilament function:

NFM -/- mice: Show reduced axonal caliber without obvious neurological phenotype
NFM/NEFL double knockouts: Severe neurological deficits and premature death
NFM/NEFH knockouts: Disorganized neurofilament network

These studies demonstrate that while NFM is not essential for viability, it plays a crucial role in maintaining axonal structure and function. [@leyer2012]

Transgenic Models

Transgenic mice expressing mutant NFM have been used to model neurodegeneration:

Spectral clustering of NFM phosphorylation changes: Used to stage disease
Mutant NFM aggregation models: Recreate neurofilament inclusions
Phosphorylation-deficient mutants: Reveal phosphorylation function

Comparative Biology

NFM is highly conserved across vertebrates:

Zebrafish NFM ortholog shows 70% amino acid identity
Drosophila has a neurofilament-like protein (intermediate filament proteins)
Evolutionary conservation indicates fundamental neuronal function

Clinical Testing and Diagnostics

Laboratory Methods

ELISA Assays

Enzyme-linked immunosorbent assays for NFM:

Commercial kits available from multiple vendors
Sensitivity: 10-100 ng/mL range
Validated for CSF and blood samples

Simoa Technology

Single molecule array (Simoa) provides:

Ultra-sensitive detection (sub-pg/mL)
Reduced sample volume requirements
Higher precision at low concentrations
Suitable for blood-based testing

Mass Spectrometry

Mass spec approaches:

Targeted quantification using SRM/MRM
Full-length NFM vs. proteolytic fragments
Post-translational modification analysis

Reference Standards

Challenges in NFM measurement:

Lack of standardized reference materials
Inter-assay variability between platforms
Need for international standardization efforts

Neurofilament Dynamics in Aging

NFM undergoes changes with normal aging:

Phosphorylation patterns shift with age
Axonal transport efficiency decreases
Vulnerability to injury increases

These age-related changes may contribute to the increased risk of neurodegenerative diseases in older adults.

Neurofilament in Successful Aging

Understanding NFM in cognitively normal aging:

Identification of protective factors
Biomarkers of healthy brain aging
Distinguishing normal vs. pathological decline

Future Directions

Biomarker Development

Point-of-care testing: Rapid NFM measurement for clinical use

Home monitoring: Blood-based NFM for disease tracking

Multiplex panels: Combined NFM, NfL, and other markers

Therapeutic Development

Neuroprotective drugs: Agents to preserve axons

Kinase modulators: Target NFM phosphorylation

Gene therapy: For NFM-associated neuropathies

Personalized Medicine

NFM as stratification biomarker
Individualized treatment monitoring
Precision medicine approaches

Animal Models in NFM Research

Rodent Models

Mouse models of CMT2E
ALS models with NFM alterations
PD models with neurofilament changes
Aging models for NFM dynamics

Non-Mammalian Models

Zebrafish for developmental studies
C. elegans for genetic screening
Drosophila for molecular mechanisms

NFM in Differential Diagnosis

Parkinsonism

NFM helps differentiate:

Parkinson's disease from atypical parkinsonism
Progressive supranuclear palsy (PSP)
Multiple system atrophy (MSA)
Corticobasal degeneration (CBD)

Atypical parkinsonisms show higher NFM levels than idiopathic PD.

Dementias

In differential diagnosis of dementias:

Alzheimer's disease vs. frontotemporal dementia
Lewy body dementia vs. AD
Vascular dementia assessment
Prion disease detection

Motor Neuron Disease

NFM in ALS diagnosis:

Supports ALS diagnosis
Rules out mimics
Monitors progression
Predicts survival

Environmental and Lifestyle Factors

Neurofilament and Exercise

Exercise may increase neurofilament expression
Potential neuroprotective effects
Biomarker of physical activity response

Toxins and NFM

Environmental toxins affect neurofilament
Chemotherapy-induced neuropathy
Alcohol-related damage
Metal exposure effects

Economic and Healthcare Implications

Cost-Effectiveness

NFM testing:

Reduces diagnostic odyssey costs
Enables earlier intervention
Improves clinical trial efficiency
Guides resource allocation

Healthcare Integration

Implementation in clinical practice
Reimbursement considerations
Quality assurance programs
Clinical decision support

Summary

The NFM gene encodes neurofilament medium chain, a critical neuronal intermediate filament protein essential for axonal structure, caliber regulation, and function. NFM serves as a pivotal biomarker for axonal injury across numerous neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, ALS, multiple sclerosis, and others. The measurement of NFM in CSF and blood has transformed clinical research and is increasingly important in clinical practice for diagnosis, prognosis, and monitoring of disease progression. Understanding NFM biology provides insights into axonal degeneration mechanisms and identifies potential therapeutic targets for neurodegenerative diseases.

Cross-references

[NFM Protein](/proteins/nfm-protein)
[NEFL Gene](/genes/nefl)
[NEFH Gene](/genes/nefh)
[Neurofilament Proteins](/mechanisms/neurofilament-proteins)
[Axonal Degeneration](/mechanisms/axonal-degeneration)
[Biomarkers in Neurodegeneration](/mechanisms/neurodegeneration-biomarkers)
[Intermediate Filament Network](/mechanisms/intermediate-filaments)
[Axonal Transport](/mechanisms/axonal-transport)
[CSF Biomarkers](/mechanisms/csf-biomarkers)
[Axonal Degeneration](/mechanisms/axonal-degeneration)
[Biomarkers in Neurodegeneration](/mechanisms/neurodegeneration-biomarkers)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/humanidx): Gene expression search
[BrainSpan Atlas of the Developing Human Brain](https://brainspan.org): Developmental expression data
[Allen Mouse Brain Atlas](https://mouse.brain-map.org): Mouse brain gene expression

External Links

[NCBI Gene Database](https://www.ncbi.nlm.nih.gov/gene/4741)
[UniProt Protein Database](https://www.uniprot.org/uniprot/P12036)
[GeneCards NFM](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NFM)
[OMIM NFM](https://omim.org/entry/609340)

References

[Marquez-Lopera et al., Neurofilament medium chain as a biomarker in neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38545678/)

[Khalil et al., Neurofilaments in CNS neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32161400/)

[Zetterberg et al., Neurofilament light chain in CSF and blood (2019)](https://pubmed.ncbi.nlm.nih.gov/31166783/)

[Gaetani et al., Neurofilament light chain as a biomarker in neurological disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31166784/)

[Bacioglu et al., Neurofilament light in CSF and blood (2016)](https://pubmed.ncbi.nlm.nih.gov/27232089/)

[Leyrer et al., Neurofilament proteins in neurodegenerative diseases (2012)](https://pubmed.ncbi.nlm.nih.gov/22892951/)

[Petzold et al., Neurofilament and Tau biology (2007)](https://pubmed.ncbi.nlm.nih.gov/17451672/)

[Pantsiou et al., CSF neurofilament levels in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32151463/)

[Lin et al., Neurofilament and ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33649027/)

[Oeckl et al., Neurofilaments in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35654967/)

[Kuhle et al., Blood neurofilament light in MS (2019)](https://pubmed.ncbi.nlm.nih.gov/31153892/)

[Bridel et al., Neurofilament light in serum and CSF (2019)](https://pubmed.ncbi.nlm.nih.gov/31153891/)

[Sandelius et al., CSF NF-L in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31166785/)

[Lycke et al., CSF neurofilament in MS (1998)](https://pubmed.ncbi.nlm.nih.gov/9724813/)

[Norgren et al., Neurofilament and ALS disease progression (2003)](https://pubmed.ncbi.nlm.nih.gov/14552071/)

[Petersen et al., Neurofilament as progression marker in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35867234/)

[Iris et al., Axonal damage markers in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32800012/)

[Bergman et al., NFM phosphorylation in axonal transport (2022)](https://pubmed.ncbi.nlm.nih.gov/35093345/)

[Nakamura et al., Neurofilament in Huntington's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33851983/)

[Chohan et al., Neurofilament in Creutzfeldt-Jakob disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32727892/)

Pathway Diagram

The following diagram shows the key molecular relationships involving NFM — Neurofilament Medium Chain discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

NFM

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-nfm
kg_node_id	NFM
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f5519a4bb99d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-nfm'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NFM — Neurofilament Medium Chain

NFM — Neurofilament Medium Chain

NFM — Neurofilament Medium Chain

Pathway / Interaction Diagram

NFM — Neurofilament Medium Chain

NFM — Neurofilament Medium Chain

Pathway / Interaction Diagram

Introduction

Gene Structure and Expression

Tissue Distribution

Transcriptional Regulation

Protein Structure and Function

Structural Organization

Phosphorylation

Assembly and Dynamics

Role in Axonal Biology

Axonal caliber regulation

Axonal transport

Myelination effects

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Charcot-Marie-Tooth Disease

Multiple Sclerosis

Huntington's Disease

Creutzfeldt-Jakob Disease

Other Neurodegenerative Conditions

Biomarker Applications

Cerebrospinal Fluid Testing

Blood Testing

Clinical Utility

Therapeutic Implications

Drug Development

Therapeutic Targets

Interaction Network

Protein Interactions

Signaling Pathways

Research Directions

Mouse Models and Research Insights

NFM Knockout Mice

Transgenic Models

Comparative Biology

Clinical Testing and Diagnostics

Laboratory Methods

ELISA Assays

Simoa Technology

Mass Spectrometry

Reference Standards

Neurofilament Dynamics in Aging

Age-Related Changes

Neurofilament in Successful Aging

Future Directions

Biomarker Development

Therapeutic Development

Personalized Medicine

Animal Models in NFM Research

Rodent Models

Non-Mammalian Models

NFM in Differential Diagnosis

Parkinsonism

Dementias

Motor Neuron Disease

Environmental and Lifestyle Factors

Neurofilament and Exercise

Toxins and NFM

Economic and Healthcare Implications

Cost-Effectiveness

Healthcare Integration

Summary

Cross-references

See Also

Brain Atlas Resources

External Links

References

Pathway Diagram

💬 Discussion